BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 10629631)

  • 1. TP53 mutations do not correlate with locoregional recurrence in stage I tongue carcinomas.
    Högmo A; Börresen-Dale AL; Blegen H; Lindholm J; Kuylenstierna R; Auer G; Munck-Wikland E
    Anticancer Res; 1999; 19(4C):3433-8. PubMed ID: 10629631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas.
    Hashimoto T; Tokuchi Y; Hayashi M; Kobayashi Y; Nishida K; Hayashi S; Ishikawa Y; Tsuchiya S; Nakagawa K; Hayashi J; Tsuchiya E
    Cancer Res; 1999 Nov; 59(21):5572-7. PubMed ID: 10554037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. P53 mutation analysis of colorectal liver metastases: relation to actual survival, angiogenic status, and p53 overexpression.
    de Jong KP; Gouw AS; Peeters PM; Bulthuis M; Menkema L; Porte RJ; Slooff MJ; van Goor H; van den Berg A
    Clin Cancer Res; 2005 Jun; 11(11):4067-73. PubMed ID: 15930341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular diagnosis of surgical margins and local recurrence in head and neck cancer patients: a prospective study.
    van Houten VM; Leemans CR; Kummer JA; Dijkstra J; Kuik DJ; van den Brekel MW; Snow GB; Brakenhoff RH
    Clin Cancer Res; 2004 Jun; 10(11):3614-20. PubMed ID: 15173067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p53 Immunostaining guided laser capture microdissection (p53-LCM) defines the presence of p53 gene mutations in focal regions of primary prostate cancer positive for p53 protein.
    Griewe GL; Dean RC; Zhang W; Young D; Sesterhenn IA; Shanmugam N; McLeod DG; Moul JW; Srivastava S
    Prostate Cancer Prostatic Dis; 2003; 6(4):281-5. PubMed ID: 14663467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patterns of p53 gene mutations in head and neck cancer: full-length gene sequencing and results of primary radiotherapy.
    Saunders ME; MacKenzie R; Shipman R; Fransen E; Gilbert R; Jordan RC
    Clin Cancer Res; 1999 Sep; 5(9):2455-63. PubMed ID: 10499619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations in the conserved regions of p53 are infrequent in betel-associated oral cancers from Papua New Guinea.
    Thomas S; Brennan J; Martel G; Frazer I; Montesano R; Sidransky D; Hollstein M
    Cancer Res; 1994 Jul; 54(13):3588-93. PubMed ID: 8012986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients.
    Alsner J; Jensen V; Kyndi M; Offersen BV; Vu P; Børresen-Dale AL; Overgaard J
    Acta Oncol; 2008; 47(4):600-7. PubMed ID: 18465328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progression in transitional cell carcinoma of the urinary bladder--analysis of Tp53 gene mutations by temperature gradients and sequence in tumor tissues and in cellular urine sediments.
    Schlechte HH; Sachs MD; Lenk SV; Brenner S; Rudolph BD; Loening SA
    Cancer Detect Prev; 2000; 24(1):24-32. PubMed ID: 10757120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abnormalities of the ARF-p53 pathway in oral squamous cell carcinoma.
    Bradley G; Irish J; MacMillan C; Mancer K; Witterick I; Hartwick W; Gullane P; Kamel-Reid S; Benchimol S
    Oncogene; 2001 Feb; 20(5):654-8. PubMed ID: 11313998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. P53 mutations in primary tumors and subsequent liver metastases are related to survival in patients with colorectal carcinoma who undergo liver resection.
    Yang Y; Forslund A; Remotti H; Lönnroth C; Andersson M; Brevinge H; Svanberg E; Lindnér P; Hafström L; Naredi P; Lundholm K
    Cancer; 2001 Feb; 91(4):727-36. PubMed ID: 11241240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TP53 and CDKN2a mutations in never-smoker oral tongue squamous cell carcinoma.
    Heaton CM; Durr ML; Tetsu O; van Zante A; Wang SJ
    Laryngoscope; 2014 Jul; 124(7):E267-73. PubMed ID: 24431303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longitudinal study of TP53 mutations in eight patients with potentially malignant oral mucosal disorders.
    Ogmundsdóttir HM; Hilmarsdóttir H; Björnsson J; Holbrook WP
    J Oral Pathol Med; 2009 Oct; 38(9):716-21. PubMed ID: 19473449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensitivity and specificity of p53 protein detection by immunohistochemistry in patients with urothelial bladder carcinoma.
    Salinas-Sánchez AS; Atienzar-Tobarra M; Lorenzo-Romero JG; Sánchez-Sánchez F; Giménez-Bachs JM; Donate-Moreno MJ; Pastor-Navarro H; Hernández-Millán I; Segura-Martín M; Escribano-Martínez J
    Urol Int; 2007; 79(4):321-7. PubMed ID: 18025850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.
    Berns EM; Foekens JA; Vossen R; Look MP; Devilee P; Henzen-Logmans SC; van Staveren IL; van Putten WL; Inganäs M; Meijer-van Gelder ME; Cornelisse C; Claassen CJ; Portengen H; Bakker B; Klijn JG
    Cancer Res; 2000 Apr; 60(8):2155-62. PubMed ID: 10786679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. APC, K-ras, and p53 gene mutations in colorectal cancer patients: correlation to clinicopathologic features and postoperative surveillance.
    Hsieh JS; Lin SR; Chang MY; Chen FM; Lu CY; Huang TJ; Huang YS; Huang CJ; Wang JY
    Am Surg; 2005 Apr; 71(4):336-43. PubMed ID: 15943410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular analysis of surgical margins in head and neck squamous cell carcinoma patients.
    Nathan CO; Amirghahri N; Rice C; Abreo FW; Shi R; Stucker FJ
    Laryngoscope; 2002 Dec; 112(12):2129-40. PubMed ID: 12461330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53 mutations and human papillomavirus infection in oral squamous cell carcinomas: correlation with overall survival.
    Kozomara R; Jović N; Magić Z; Branković-Magić M; Minić V
    J Craniomaxillofac Surg; 2005 Oct; 33(5):342-8. PubMed ID: 16129609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53 mutations in epithelial ovarian cancers: possible role in predicting chemoresistance.
    Laframboise S; Chapman W; McLaughlin J; Andrulis IL
    Cancer J; 2000; 6(5):302-8. PubMed ID: 11079169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p53 mutation is infrequent in clear cell carcinoma of the ovary.
    Ho ES; Lai CR; Hsieh YT; Chen JT; Lin AJ; Hung MH; Liu FS
    Gynecol Oncol; 2001 Feb; 80(2):189-93. PubMed ID: 11161858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.